Reports preliminary FY25 revenue $100M, consensus $97.78M. “2025 was an important year for NeuroPace (NPCE) as we delivered strong growth, strengthened the core RNS business, and advanced our strategic priorities,” said Joel Becker, CEO of NeuroPace. “Our preliminary results reflect robust demand for RNS, disciplined execution, and a business that is increasingly focused on high margin, high impact personalized neuromodulation. As we look to 2026, we believe we are very well positioned to drive durable growth, expand access to RNS therapy in existing and new indications, and continue progress toward our long-term profitability objectives.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NPCE:
- NeuroPace Initiated With Buy on Breakthrough RNS Label Expansion Opportunity and Strong NAUTILUS Efficacy Data
- NeuroPace files premarket approval supplement application for RNS System
- NeuroPace price target raised to $22 from $18 at UBS
- NeuroPace price target raised to $20 from $18 at JPMorgan
- Buy Rating Affirmed on Promising NAUTILUS Trial Results and Potential FDA Consideration